Scientists hunt for biomarkers to personalize stomach cancer treatment

NCT ID NCT05508399

Completed Knowledge-focused Sponsor: Xijing Hospital Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study analyzed blood and tumor tissue samples from 28 people with stomach cancer to find biological markers that predict how well immunotherapy (tislelizumab) combined with chemotherapy works before surgery. The goal was to build a model that uses RNA and other factors to forecast treatment success. Since it's an observational study, it does not test a new treatment but aims to improve future treatment decisions.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could help doctors predict which patients with stomach cancer will benefit most from combining immunotherapy with chemotherapy before surgery.
What could go wrong: This is a small, completed observational study (28 participants) that identifies potential biomarkers, not a treatment trial. The findings need validation in larger studies before they can guide patient care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

gastric adenocarcinoma gastroesophageal junction adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LOCALLY ADVANCED GASTRIC ADENOCARCINOMA PD-1

Contacts and locations

Locations

Xijing Hospital of Digestive Diseases

Xi'an, Shaanxi, 710000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.